Department of Obstetrics and Gynecology, University of Rostock, Germany.
Breast Care (Basel). 2014 Dec;9(6):391-6. doi: 10.1159/000369573.
Breast cancer is the most common cancer of women in Western Europe and North America. Effective strategies of medical prevention could reduce the burden of breast cancer mortality. The best evidence for a risk reduction exists for hormonal agents such as tamoxifen and raloxifene (22-72%) or aromatase inhibitors (50-65%). However, the severity of side effects and the lack of evidence for an improved survival compromise the risk/benefit balance. In this review the results of chemoprevention studies, including new treatment approaches, are summarized with critical discussion of their use in clinical practice.
乳腺癌是西欧和北美的女性最常见的癌症。有效的医学预防策略可以降低乳腺癌死亡率的负担。激素药物如他莫昔芬和雷洛昔芬（22-72%）或芳香酶抑制剂（50-65%）的风险降低证据最好。然而，副作用的严重程度和缺乏生存改善的证据影响了风险/效益平衡。在这篇综述中，总结了化学预防研究的结果，包括新的治疗方法，并对其在临床实践中的应用进行了批判性讨论。
